296 related articles for article (PubMed ID: 25865354)
21. Stromal
da Silva EM; Beca F; Sebastiao APM; Murray MP; Silveira C; Da Cruz Paula A; Pareja F; Wen HY; D'Alfonso TM; Edelweiss M; Weigelt B; Brogi E; Reis-Filho JS; Zhang H
J Clin Pathol; 2022 Feb; 75(2):133-136. PubMed ID: 33376197
[TBL] [Abstract][Full Text] [Related]
22. Next-Gen Sequencing Exposes Frequent MED12 Mutations and Actionable Therapeutic Targets in Phyllodes Tumors.
Cani AK; Hovelson DH; McDaniel AS; Sadis S; Haller MJ; Yadati V; Amin AM; Bratley J; Bandla S; Williams PD; Rhodes K; Liu CJ; Quist MJ; Rhodes DR; Grasso CS; Kleer CG; Tomlins SA
Mol Cancer Res; 2015 Apr; 13(4):613-9. PubMed ID: 25593300
[TBL] [Abstract][Full Text] [Related]
23. Droplet-digital PCR reveals frequent mutations in TERT promoter region in breast fibroadenomas and phyllodes tumours, irrespective of the presence of MED12 mutations.
Otsuji K; Sasaki T; Tanabe M; Seto Y
Br J Cancer; 2021 Jan; 124(2):466-473. PubMed ID: 33046803
[TBL] [Abstract][Full Text] [Related]
24. Periductal Stromal Tumor of the Breast with a
Anderson B; Marotti JD; Lefferts JA; Muller KE
Int J Surg Pathol; 2023 Dec; 31(8):1626-1631. PubMed ID: 36823780
[TBL] [Abstract][Full Text] [Related]
25. MED12 somatic mutations encompassing exon 2 associated with benign breast fibroadenomas and not breast carcinoma in Indian women.
Darooei M; Khan F; Rehan M; Zubeda S; Jeyashanker E; Annapurna S; Shah A; Maddali S; Hasan Q
J Cell Biochem; 2019 Jan; 120(1):182-191. PubMed ID: 30230586
[TBL] [Abstract][Full Text] [Related]
26. Exomic landscape of MED12 mutation-negative and -positive uterine leiomyomas.
Mäkinen N; Vahteristo P; Bützow R; Sjöberg J; Aaltonen LA
Int J Cancer; 2014 Feb; 134(4):1008-12. PubMed ID: 23913526
[TBL] [Abstract][Full Text] [Related]
27. Highly heterogeneous genomic landscape of uterine leiomyomas by whole exome sequencing and genome-wide arrays.
Yatsenko SA; Mittal P; Wood-Trageser MA; Jones MW; Surti U; Edwards RP; Sood AK; Rajkovic A
Fertil Steril; 2017 Feb; 107(2):457-466.e9. PubMed ID: 27889101
[TBL] [Abstract][Full Text] [Related]
28. Genome-wide analysis for loss of heterozygosity in primary and recurrent phyllodes tumor and fibroadenoma of breast using single nucleotide polymorphism arrays.
Wang ZC; Buraimoh A; Iglehart JD; Richardson AL
Breast Cancer Res Treat; 2006 Jun; 97(3):301-9. PubMed ID: 16791486
[TBL] [Abstract][Full Text] [Related]
29. Missense mutations in exon 2 of the MED12 gene are involved in IGF-2 overexpression in uterine leiomyoma.
Di Tommaso S; Tinelli A; Malvasi A; Massari S
Mol Hum Reprod; 2014 Oct; 20(10):1009-15. PubMed ID: 25015674
[TBL] [Abstract][Full Text] [Related]
30. Mediator complex subunit 12 exon 2 mutation analysis in different subtypes of smooth muscle tumors confirms genetic heterogeneity.
de Graaff MA; Cleton-Jansen AM; Szuhai K; Bovée JV
Hum Pathol; 2013 Aug; 44(8):1597-604. PubMed ID: 23517922
[TBL] [Abstract][Full Text] [Related]
31. MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas.
Mäkinen N; Mehine M; Tolvanen J; Kaasinen E; Li Y; Lehtonen HJ; Gentile M; Yan J; Enge M; Taipale M; Aavikko M; Katainen R; Virolainen E; Böhling T; Koski TA; Launonen V; Sjöberg J; Taipale J; Vahteristo P; Aaltonen LA
Science; 2011 Oct; 334(6053):252-5. PubMed ID: 21868628
[TBL] [Abstract][Full Text] [Related]
32. MED12, TERT promoter and RBM15 mutations in primary and recurrent phyllodes tumours.
Garcia-Dios DA; Levi D; Shah V; Gillett C; Simpson MA; Hanby A; Tomlinson I; Sawyer EJ
Br J Cancer; 2018 Jan; 118(2):277-284. PubMed ID: 29315289
[TBL] [Abstract][Full Text] [Related]
33. Mutations in Exon 1 highlight the role of MED12 in uterine leiomyomas.
Kämpjärvi K; Park MJ; Mehine M; Kim NH; Clark AD; Bützow R; Böhling T; Böhm J; Mecklin JP; Järvinen H; Tomlinson IP; van der Spuy ZM; Sjöberg J; Boyer TG; Vahteristo P
Hum Mutat; 2014 Sep; 35(9):1136-41. PubMed ID: 24980722
[TBL] [Abstract][Full Text] [Related]
34. Factors targeting
Bullerdiek J; Rommel B
F1000Res; 2018; 7():359. PubMed ID: 30647905
[TBL] [Abstract][Full Text] [Related]
35. Prevalence of MED12 mutations in uterine and extrauterine smooth muscle tumours.
Matsubara A; Sekine S; Yoshida M; Yoshida A; Taniguchi H; Kushima R; Tsuda H; Kanai Y
Histopathology; 2013 Mar; 62(4):657-61. PubMed ID: 23347103
[TBL] [Abstract][Full Text] [Related]
36. Fibroepithelial lesions; The WHO spectrum.
Krings G; Bean GR; Chen YY
Semin Diagn Pathol; 2017 Sep; 34(5):438-452. PubMed ID: 28688536
[TBL] [Abstract][Full Text] [Related]
37. Comprehensive screening for MED12 mutations in gynaecological mesenchymal tumours identified morphologically distinctive mixed epithelial and stromal tumours.
Yuan CT; Huang WC; Lee CH; Lin MC; Lee CH; Kao YC; Huang HY; Kuo KT; Lee JC
Histopathology; 2017 May; 70(6):954-965. PubMed ID: 28002623
[TBL] [Abstract][Full Text] [Related]
38. Loss of imprinting of IGF2 in fibroadenomas and phyllodes tumors of the breast.
Mishima C; Kagara N; Tanei T; Naoi Y; Shimoda M; Shimomura A; Shimazu K; Kim SJ; Noguchi S
Oncol Rep; 2016 Mar; 35(3):1511-8. PubMed ID: 26676988
[TBL] [Abstract][Full Text] [Related]
39. MED12 exon 2 mutations in histopathological uterine leiomyoma variants.
Mäkinen N; Vahteristo P; Kämpjärvi K; Arola J; Bützow R; Aaltonen LA
Eur J Hum Genet; 2013 Nov; 21(11):1300-3. PubMed ID: 23443020
[TBL] [Abstract][Full Text] [Related]
40. The study of MED12 gene mutations in uterine leiomyomas from Iranian patients.
Sadeghi S; Khorrami M; Amin-Beidokhti M; Abbasi M; Kamalian Z; Irani S; Omrani M; Azmoodeh O; Mirfakhraie R
Tumour Biol; 2016 Feb; 37(2):1567-71. PubMed ID: 26298726
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
